Kevin Kabler is a partner in Goodwin’s Technology Companies and Life Sciences group. He specializes in building and managing patent portfolios for life sciences companies and institutions, particularly in the fields of immuno-oncology, antibodies, cell therapy, gene therapy, precision medicine, vaccines, genetics, biologics, RNAi, stem cells, and immunotherapy.

His practice involves strategic patent counseling and due diligence for clients at all stages of the business cycle, in addition to analysis and evaluation of third-party patents for mitigation of assertion risks and for investment purposes. He has extensive experience preparing and prosecuting domestic and international patent applications, and advising investors in assessing the competitive landscape, technology and intellectual property assets, and the risks associated with target investments.

Mr. Kabler has a wealth of experience in the natural sciences, with particular experience in immuno-oncology and immunotherapy, including issues involving checkpoint inhibitors, CAR-T cells, and cancer vaccines. He has counseled numerous leading companies, with technologies ranging from antibodies to personalized cancer vaccines, on the protection and exploitation of their intellectual property. Mr. Kabler is also an expert on technology that combines traditional biomedical research with data science.

Prior to joining Goodwin in 2019, Mr. Kabler was a partner at Fenwick & West LLP. Before joining Fenwick & West, Mr. Kabler was a post-doctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.

Areas of Practice
Domaines D’Expertise





Mr. Kabler’s representative experience includes IP due diligence in the following deals:

  • Forty Seven, Inc. in its $4.9 billion acquisition by Gilead 
  • Pionyr Immunotherapeutics Inc. in its $275 million exclusive option to be acquired by Gilead 
  • Connect Biopharma in its $115 million Series C financing 
  • Gritstone Oncology in its (i) initial public offering*, (ii) follow on public offering, and (iii) collaboration with bluebird bio, in which bluebird paid $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs)
  • Arsenal Biosciences in its $86 million Series A financing
  • Iconic Therapeutics in its exclusive option and license agreement with Exelixis, Inc. to advance an innovative next-generation antibody-drug conjugate (ADC) program
  • ArrowMark Partners in its $110 million Series B investment in Precision Biosciences*
  • PACT Pharma Inc. in its $95 million Series B financing*
  • Pionyr Immunotherapeutics Inc. in its $62 million Series B financing*
  • Gritstone Oncology in its $97.5 Million Series B financing*
  • ProNAi Therapeutics in its $158.4 Million initial public offering*

* Denotes experience prior to joining Goodwin

In The News









J.D., 2011
University of California, Hastings College of the Law

(magna cum laude, Order of the Coif, Thurston Honor Society)

Ph.D., Immunology, 2005
Baylor College of Medicine
B.S., Microbiology, 2001
Kansas State University

(cum laude)



U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique